Third Psychoactive Drug Usage Guide.
D000662:Amphetamines / Q000627:therapeutic use; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D001007:Anxiety / Q000188:drug therapy; D001714:Bipolar Disorder / Q000188:drug therapy; D002090:Butyrophenones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010640:Phenothiazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy*; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D046948:Secologanin Tryptamine Alkaloids / Q000627:therapeutic use; D013892:Thioxanthenes / Q000627:therapeutic use
D000662:Amphetamines; D014151:Anti-Anxiety Agents; D000929:Antidepressive Agents, Tricyclic; D002090:Butyrophenones; D008996:Monoamine Oxidase Inhibitors; D010640:Phenothiazines; D011619:Psychotropic Drugs; D046948:Secologanin Tryptamine Alkaloids; D013892:Thioxanthenes; D008094:Lithium